Profile cover photo
Profile photo
Cidara
3 followers -
Cidara is a biotechnology company developing novel anti-infectives to address serious infections. Our initial focus is on the treatment and prevention of devastating fungal infections through innovative small molecules and immunotherapeutics.
Cidara is a biotechnology company developing novel anti-infectives to address serious infections. Our initial focus is on the treatment and prevention of devastating fungal infections through innovative small molecules and immunotherapeutics.

3 followers
About
Cidara's posts

Post has attachment
Public
Cidara Therapeutics has reported unfavorable results of Phase 2 RADIANT trial of CD101 Topical in acute vulvovaginal candidiasis (VVC). Cidara's management will host a conference call and webcast today at 5:30 am PT / 8:30 am ET. For more information visit:

Post has attachment
Public
Rapid drug development is a key factor in the battle against antimicrobial resistance. Cidara's CEO, Dr. Jeffrey Stein, calls for a collaborative approach between industry, government and researchers to improve the regulatory and commercial environments for new anti-infectives, and spur the pipeline of antibiotic and antifungal development in his new Drug Discovery and Development article.

Post has attachment
Public
Systemic fungal infections are a common cause of hospital-acquired infections and constitute a disproportionate percentage of mortalities in infectious disease. Jeffrey Stein, Cidara's CEO, shines a light on the lesser-known challenges of systemic fungal infections and outlines how healthcare organizations can help.

Post has attachment
Public
Cidara's CEO, Dr. Jeffrey Stein, discusses the rise in systemic fungal infections and what healthcare organizations can do to help in his new Becker's Hospital Review article.

Post has attachment
Public
Cidara's CEO, Jeffrey Stein, Ph.D., has been elected as the new Chairman of the Antimicrobials Working Group (AWG). The AWG is an industry-led, 501(c)(6) comprised of emerging antimicrobials companies whose objective is to improve the regulatory, investment and commercial environment for antimicrobial drug development. For more info visit:

Post has attachment
Public
Cidara has completed patient enrollment in the RADIANT trial, a Phase 2 randomized trial evaluating the safety, tolerability and efficacy of two topical treatment regimens of the novel echinocandin antifungal, CD101, in women with moderate to severe acute vulvovaginal candidiasis (VVC). The primary endpoint for the RADIANT trial is the safety and tolerability of two doses of CD101 Gel versus a single dose of CD101 Ointment in patients with an episode of moderate to severe acute VVC. Cidara expects to report topline data for RADIANT in the first quarter of 2017. For more information visit:

Post has attachment
Public
Data from Cidara's preclinical and clinical studies evaluating the company’s novel echinocandin antifungal CD101 appear in the December 5 online issue of the journal Antimicrobial Agents and Chemotherapy (AAC). “The publication of these latest findings in AAC further affirms the clinical utility, safety and unique profile of CD101 across a number of infectious-disease indications, including treatment and prophylaxis of invasive fungal infections and treatment of vulvovaginal candidiasis,” said Jeffrey Stein, Ph.D., president and CEO of Cidara. Learn more:

Post has attachment
Public
Cidara will present data from its preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego from December 3-6, 2016. “We are pleased to be sharing data at this year’s ASH meeting that demonstrate the potential of our novel compound CD101 to treat and prevent deadly fungal infections in blood cancer patients,” said Jeffrey Stein, Ph.D., president and CEO of Cidara. Click for more info:

Post has attachment
Public
Cidara's CD201 may circumvent existing bacterial resistance mechanisms and introduce a new mechanism of immune-mediated killing, potentially providing a novel tool for fighting antibiotic resistant pathogens.

Post has attachment
Public
This infographic from the CDC shows how antibiotic resistance occurs. Cidara is using our proprietary Cloudbreak immunotherapy discovery platform as a fundamentally new approach to treat antibiotic resistant infections by using the patient’s immune system. Learn more on our website: http://bit.ly/2dFLv1c
Photo
Wait while more posts are being loaded